logo
What is chronic venous insufficiency? Everything to know about Trump's diagnosis

What is chronic venous insufficiency? Everything to know about Trump's diagnosis

Yahoo18-07-2025
President Donald Trump has been diagnosed with chronic venous insufficiency, the White House announced on Thursday.
Press Secretary Karoline Leavitt shared a letter from Trump's physician in a news conference, which said Trump was examined after he noticed "mild" swelling in his legs.
Leavitt said the physician described the condition as "benign" and "common," particularly among adults above age 70.
MORE: Gal Gadot reveals she had 'massive blood clot' in brain while pregnant
Leavitt added that the president is in "excellent health" and that the doctor's full letter would be released soon.
Here's what you need to know about the condition, what symptoms it causes and how it's treated.
What is chronic venous insufficiency?
Chronic venous insufficiency (CVI) is a circulatory condition in which the veins in the leg have difficulty returning blood back to the heart due to damaged valves.
"Unlike the arteries, the veins have valves that help return blood to the heart," Dr. Andrea Obi, vascular surgeon at University of Michigan Health Frankel Cardiovascular Center and associate professor of vascular surgery at University of Michigan Medical School, told ABC News.
She explained that there are larger veins, called deep veins, which return the bulk of blood to the heart, and there are superficial veins, which are just under the skin surface.
"When the valves fail, meaning they don't adequately return blood to the heart, the blood can back up into the leg, and that's essentially what venous insufficiency is," Obi said.
This can cause blood to pool in the legs and lead to leg swelling.
MORE: Tori Kelly hospitalized: What you need to know about blood clots
CVI is fairly common, affecting up to 40% of the U.S. population, according to the Society for Vascular Surgery.
Obi said this figure may be an underestimation because CVI is not detected on any routine screening test, and patients often require a duplex ultrasound -- a non-invasive imaging technique to assess blood flow and blood vessel structure -- for diagnosis.
What are the symptoms?
Obi said most CVI patients have mild symptoms and the most common manifestation is varicose veins, which occur when the blood pools into the superficial veins just under the skin.
The veins become swollen, which can be heavy, uncomfortable or painful for patients.
If patients have CVI in the deeper veins, they may experience leg swelling around the ankle area and it can extend up towards the knee, Obi said.
In more severe cases, darkening of the skin can occur and an open sore or ulcer could develop.
"When the blood pools down near the ankle level, you'll get discoloration, and it's a brown discoloration … and that brown discoloration is the result of the iron from the red blood cells that sort of pools there and gets picked up by your immune cells," Obi said.
Over time, this can make the skin thick and unable to heal from minor trauma, which is when ulcers form, she said.
How is it treated?
Treatments are typically nonsurgical and are mainly to prevent swelling and ulcers from forming, according to the Society for Vascular Surgery.
Obi said if a patient is found to have CVI incidentally and they don't have symptoms, there is no need for treatment unless symptoms arise.
First-line treatment can include compression, such as wearing compression stockings or an elastic wrap. There are also supplements patients can take to relieve symptoms, Obi said.
MORE: Singer Tori Kelly being treated for multiple blood clots after collapsing
"Compression is the very first thing that you prescribe and then, generally, if a patient desires surgical intervention or something like that, you would try compression first to see if they get relief," she said. "If they're still symptomatic or not able to live their daily life, then you might proceed down the pathway of doing an intervention to try and help them improve their quality of life."
If superficial veins are affected, patients may receive vein ablation, which is a minimally invasive procedure to close the veins off, and removal of the varicose veins.
If deep veins are affected, some patients may require an angioplasty to widen the narrow or blocked veins, or stenting to restore blood flow.
Obi said even if someone's vein valves are prone to failing due to genetics or aging, walking can help overcome this.
"Your calf muscle will substitute for your valves, and your calf muscle will actually push the blood back up to your heart," she said. "We tell all our patients, 'You should do some sort of walking program to keep that calf pump strong. The worst thing you can do is stand on your feet for long periods of time and allow the blood to pool."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kyverna Appoints New CFO to Guide Next Growth Phase
Kyverna Appoints New CFO to Guide Next Growth Phase

Yahoo

time2 hours ago

  • Yahoo

Kyverna Appoints New CFO to Guide Next Growth Phase

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 30, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced that Marc Grasso, M.D. has been appointed as the company's new Chief Financial Officer (CFO). Before joining Kyverna Therapeutics, Inc. (NASDAQ:KYTX), Dr. Grasso was serving as CFO at Alector, Inc., a biotechnology company focused on neurodegenerative diseases. There, he oversaw financial planning, investor relations, accounting, IT, and facilities. Dr. Grasso earned his medical degree from Johns Hopkins University School of Medicine, where he also performed research in molecular oncology. He holds a Bachelor of Arts degree in molecular biology with honors from Princeton University. A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. Dr. Grasso has over 25 years of experience working with public companies, capital markets, and investment banking. He is taking over from Ryan Jones, MBA, who is moving to a strategic advisor role to help with a smooth transition. The new CFO is expected to use his experience to help Kyverna Therapeutics, Inc. (NASDAQ:KYTX) bring the first CAR T-cell therapy for autoimmune diseases to the market while also guiding the company's business and financial plans. As Kyverna Therapeutics, Inc. (NASDAQ:KYTX) works to speed up its clinical development and commercialization efforts, Dr. Grasso's leadership will play a crucial role in supporting the company's next phase of growth. Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company committed to developing cell therapies for patients suffering from autoimmune diseases. While we acknowledge the potential of KYTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)
Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)

Yahoo

time2 hours ago

  • Yahoo

Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)

Alto Neuroscience, Inc. (NYSE:ANRO) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 26, Stifel reiterated its 'Buy' rating on Alto Neuroscience, Inc. (NYSE:ANRO) with a price target of $10. This decision came after the company announced Phase 2 proof-of-concept results for its drug ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. A close-up of a healthcare professional in a lab coat, handling a pipette with medications for neuroscience diseases. The trial showed mixed results. However, Stifel analysts noted that ALTO-203 showed significant positive effects in improving sustained attention and increased wakefulness. The strongest results were seen in patients with more abnormal theta/beta EEG ratios at baseline, which is a biomarker that can be used to help diagnose ADHD. Stifel described the trial as exploratory with low expectations, noting that although this program keeps some options open for Alto Neuroscience, Inc. (NYSE:ANRO), it does not change the core investment view as the company prioritizes its late-stage pipeline. The next steps for ALTO-203 are yet to be determined. Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on the development of treatment options for neuropsychiatric disorders. While we acknowledge the potential of ANRO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

What to know about CTE, the brain disease, after NYC gunman's claims
What to know about CTE, the brain disease, after NYC gunman's claims

Yahoo

time2 hours ago

  • Yahoo

What to know about CTE, the brain disease, after NYC gunman's claims

Chronic traumatic encephalopathy, or CTE, is a brain disease linked to repeated hits to the head, often seen in military veterans and athletes including football players, hockey players and boxers. It causes symptoms, which usually appear years after the head trauma, including memory loss, mood changes, confusion and trouble thinking clearly. The 27-year-old man who allegedly shot and killed four people at a Midtown Manhattan office building on Monday carried a note in his pocket claiming he suffered from the disease, police sources told ABC News, though there is no evidence so far to confirm he had the condition. MORE: Manhattan shooting suspect claimed to have CTE, mentioned NFL in note, sources say Suspect Shane Tamura died by suicide after the Monday mass shooting at 345 Park Avenue, police said. Tamura, 27, played high school football in Los Angeles but did not play professionally, according to sources. Police have found no evidence so far that he suffered a traumatic brain injury, sources said. There is currently no evidence of a relationship between the suspect and the military or the NFL. CTE cannot be diagnosed in a living person with certainty, but doctors may suspect it based on symptoms and history of head trauma. The only way to confirm CTE is through an autopsy by specialists who look for specific changes in the brain. Researchers analyze the brain's post-mortem to look for changes to tau proteins, found in neurons, that define CTE. The Boston University UNITE Brain Bank holds more than 1,500 donated brains, including more than 800 confirmed cases of CTE. Most donors were athletes or military veterans with a history of repeated head impacts. ABC News' Aaron Katersky contributed to this report. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store